Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

What Was Tested

The trial (phase 3) is built around Semaglutide.

The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes.

The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength.

Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing.

It had 1 arm (groups): Type 2 Diabetics on Semaglutide (experimental).

The registry classes the interventions as drug.

More on the Plan

These effects are amplified in older women, who already experience age-related declines in muscle and bone health following menopause.

The implications of these changes for muscle strength, bone turnover, and bone mineral density remain unclear, particularly in older females with type 2 diabetes who may be more vulnerable to muscle and bone loss.

Existing data on GLP-1 RAs and fracture risk are limited and inconsistent, and most prior studies have evaluated older, less potent agents with minimal weight-loss effects.

This prospective observational study is designed to characterize changes in muscle and bone health during 6 months of GLP-1 RA therapy in older females with type 2 diabetes who are receiving treatment as part of routine clinical care.

Who Took Part

Enrollment: 20 planned participants were the target.

It was open to women only aged from 65 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Postmenopausal women aged 65 years or older. Has type 2 diabetes. Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive). Willingness and ability to comply with all study procedures, including fasting requirements for certain visits. No osteoporosis confirmed on DEXA scan within 12 months.

The full record lists 7 inclusion and 21 exclusion criteria; among the exclusions: patients with type 1 diabetes mellitus or other types of diabetes that are not t2d; patients with a history of treatment with anti-osteoporosis agents; documented primary or secondary osteoporosis on a dexa scan within the last 12 months, or are on osteoporosis therapies.

How the Study Was Run

The set-up was single-group and open-label.

Being open-label, the Semaglutide study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-05-07 with completion listed for 2028-11.

It ran at 1 site in United States.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in handgrip strength (time frame: Baseline, week4, week 8, week12, week 26).

It also tracked 10 secondary outcomes, for example Change in bone turnover markers, Change in timed up-and-go (TUG), Change in HbA1c, Change in fasting glucose, Change in weight and Change in FRAX score.

What This Means in Plain Language

Put simply, this is a phase 3 trial of Semaglutide in 20 people.

Its size is small, so on its own it can only give an early look.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.